Lejeune F J, Regnier R, Nogaret J M, Jabri M
Recent Results Cancer Res. 1983;86:204-8. doi: 10.1007/978-3-642-82025-0_34.
In order to avoid amputation, which does not seem to improve survival in osteosarcoma, we have initiated a limb-preservation program using intra-arterial radiosensitization. Eleven osteosarcomas with soft tissue involvement and six other bone malignancies were prospectively treated according to the following protocol: (a) surgical insertion of an intra-arterial catheter through a Dacron patch, (b) intra-arterial infusion of 15 mg/kg BUDR on days 1-2 every 5 days for 40 days, (c) 600 rads flash irradiation on day 3 every 5 days, X 8. Median follow-up time has been 36 months. In the osteosarcoma group, median survival has been 12 months. Four of the five osteosarcoma patients who died had received prophylactic HD methotrexate-vincristine-adriamycin systemic chemotherapy; one patient refused.
为避免截肢（在骨肉瘤中截肢似乎并不能提高生存率），我们启动了一项采用动脉内放射增敏的保肢计划。11例伴有软组织受累的骨肉瘤患者和6例其他骨恶性肿瘤患者按照以下方案进行前瞻性治疗：(a) 通过涤纶补片手术插入动脉内导管；(b) 每5天在第1 - 2天动脉内输注15 mg/kg溴脱氧尿苷，共40天；(c) 每5天在第3天进行600拉德的快速照射，共8次。中位随访时间为36个月。在骨肉瘤组中，中位生存期为12个月。死亡的5例骨肉瘤患者中有4例接受了预防性大剂量甲氨蝶呤 - 长春新碱 - 阿霉素全身化疗；1例患者拒绝。
